Lipophilic Statins Deplete GPX4 to Promote Ferroptosis and Sensitize Cancer Cells to Immune Checkpoint Blockade

Area of Science:

• Oncology
• Immunology
• Biochemistry

Background:

• Statins exhibit anticancer properties, but their mechanisms remain unclear.
• Understanding statin-induced cell death pathways is crucial for cancer therapy.
• Ferroptosis is an emerging target in cancer immunotherapy.

Purpose of the Study:

• To investigate statins' ability to induce cell death and ferroptosis in melanoma and colorectal cancer.
• To elucidate the molecular mechanisms underlying statin-induced ferroptosis.
• To evaluate the therapeutic potential of combining statins with immunotherapy.

Main Methods:

• Utilized patient-derived melanoma cell lines and colorectal cancer models.
• Analyzed gene expression related to the mevalonate pathway and ferroptosis.
• Investigated the role of mevalonate and its derivatives in statin-induced cell death.
• Conducted in vivo studies combining simvastatin with α-PD1 immunotherapy.

Main Results:

• Statins induced cell death with ferroptosis features in cancer cells.
• Lower mevalonate pathway gene expression correlated with better melanoma patient survival.
• Mevalonate supplementation rescued statin-induced cell death.
• Simvastatin combined with α-PD1 immunotherapy led to near-complete tumor clearance and extended survival in mice.

Conclusions:

• Lipophilic statins induce ferroptosis by affecting GPX4 synthesis via the mevalonate pathway.
• Statins hold therapeutic potential, especially when combined with immunotherapies like α-PD1.
• This study highlights a novel therapeutic strategy for melanoma and potentially other cancers.